ASCO GU 2023: Adjuvant Nivolumab Benefit Persists in High-Risk Muscle-Invasive Urothelial Carcinoma
Effect of nivolumab is ‘remarkably stable’ at median 36.1 months of follow-up
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.